Cargando…

NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics

The NLRP3 inflammasome is a crucial constituent of the body’s innate immune system, and a multiprotein platform which is initiated by pattern recognition receptors (PRRs). Its activation leads to caspase-1 maturation and release of inflammatory cytokines, interleukin-1β (IL-1β) and IL-18, and subseq...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Na, Cheng, Weijia, Liu, Dongling, Liu, Gang, Cui, Can, Feng, Chaoli, Wang, Xianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045366/
https://www.ncbi.nlm.nih.gov/pubmed/35493086
http://dx.doi.org/10.3389/fcell.2022.823387
_version_ 1784695300787535872
author Lu, Na
Cheng, Weijia
Liu, Dongling
Liu, Gang
Cui, Can
Feng, Chaoli
Wang, Xianwei
author_facet Lu, Na
Cheng, Weijia
Liu, Dongling
Liu, Gang
Cui, Can
Feng, Chaoli
Wang, Xianwei
author_sort Lu, Na
collection PubMed
description The NLRP3 inflammasome is a crucial constituent of the body’s innate immune system, and a multiprotein platform which is initiated by pattern recognition receptors (PRRs). Its activation leads to caspase-1 maturation and release of inflammatory cytokines, interleukin-1β (IL-1β) and IL-18, and subsequently causes pyroptosis. Recently, the excess activation of NLRP3 inflammasome has been confirmed to mediate inflammatory responses and to participate in genesis and development of atherosclerosis. Therefore, the progress on the discovery of specific inhibitors against the NLRP3 inflammasome and the upstream and downstream inflammatory factors has become potential targets for clinical treatment. Here we review the recently described mechanisms about the NLRP3 inflammasome activation, and discuss emphatically the pharmacological interventions using statins and natural medication for atherosclerosis associated with NLRP3 inflammasome.
format Online
Article
Text
id pubmed-9045366
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90453662022-04-28 NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics Lu, Na Cheng, Weijia Liu, Dongling Liu, Gang Cui, Can Feng, Chaoli Wang, Xianwei Front Cell Dev Biol Cell and Developmental Biology The NLRP3 inflammasome is a crucial constituent of the body’s innate immune system, and a multiprotein platform which is initiated by pattern recognition receptors (PRRs). Its activation leads to caspase-1 maturation and release of inflammatory cytokines, interleukin-1β (IL-1β) and IL-18, and subsequently causes pyroptosis. Recently, the excess activation of NLRP3 inflammasome has been confirmed to mediate inflammatory responses and to participate in genesis and development of atherosclerosis. Therefore, the progress on the discovery of specific inhibitors against the NLRP3 inflammasome and the upstream and downstream inflammatory factors has become potential targets for clinical treatment. Here we review the recently described mechanisms about the NLRP3 inflammasome activation, and discuss emphatically the pharmacological interventions using statins and natural medication for atherosclerosis associated with NLRP3 inflammasome. Frontiers Media S.A. 2022-04-13 /pmc/articles/PMC9045366/ /pubmed/35493086 http://dx.doi.org/10.3389/fcell.2022.823387 Text en Copyright © 2022 Lu, Cheng, Liu, Liu, Cui, Feng and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Lu, Na
Cheng, Weijia
Liu, Dongling
Liu, Gang
Cui, Can
Feng, Chaoli
Wang, Xianwei
NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title_full NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title_fullStr NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title_full_unstemmed NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title_short NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics
title_sort nlrp3-mediated inflammation in atherosclerosis and associated therapeutics
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045366/
https://www.ncbi.nlm.nih.gov/pubmed/35493086
http://dx.doi.org/10.3389/fcell.2022.823387
work_keys_str_mv AT luna nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT chengweijia nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT liudongling nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT liugang nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT cuican nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT fengchaoli nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics
AT wangxianwei nlrp3mediatedinflammationinatherosclerosisandassociatedtherapeutics